Tests spinal fluid proteins to predict multiple sclerosis outlook
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study checks specific proteins in spinal fluid to see whether they can predict how multiple sclerosis (or related symptoms like optic neuritis) may go over time. It may help doctors better estimate prognosis using results from tests you may already be having.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have multiple sclerosis or optic neuritis (a condition that can be part of the early MS spectrum)
- You must be able to have a lumbar puncture (spinal tap) as part of routine testing
- You must also have a brain MRI as part of routine testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a protein called FCRL5 in the blood of people with multiple sclerosis (MS), as well as healthy volunteers and people with Sjögren's syndrome. The goal is to understand how this protein relates to MS and how it might affect treatment response. If you have MS and are about to start a new treatment, you may be able to join.
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
This study looks at a blood marker called TWEAK to see if it can signal when multiple sclerosis or its first symptoms might flare up again. If you join, your blood would be checked at regular visits to help predict future inflammation.
This study looks at certain proteins in the blood of people with progressive MS to see if they can predict how the disease will progress. It may help doctors understand and manage the condition better.
This study looks at a protein called kappa free light chains (KFLC) in the spinal fluid and blood of people with multiple sclerosis (MS) or a first MS-like episode (CIS). The goal is to better understand how this protein relates to the disease, which may help with diagnosis and monitoring.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.